Physicians' Academy for Cardiovascular Education

What is the clinical evidence for the benefits of GLP-1RAs?

5 Things a cardiologist needs to know about GLP-1 RA

*NEW* Subtitling in English, German, Italian, Spanish, French, and Chinese

10' education - Dec. 10, 2020 - Prof. Subodh Verma, MD - Toronto, ON, Canada - Online CME

Video navigation menu

  • Pathophysiology of CVD in diabetes  00:29
  • Clinical trials led to changes in European and US treatment guidelines  01:50
  • CV events of the various trials more in detail 07:55
  • How do GLP-1RAs reduce ischemic events? 10:51
  • Ongoing clinical trials with GLP-1RA 13:07


Show transcript

Educational information

This educational video is part of a series called '5 Things a cardiologist needs to know about GLP-1RA' that are aimed to guide cardiologists in management of patients with type 2 diabetes, since the cardiology practice is increasingly confronted with these patients. This series covers five topics that help cardiologists understand why GLP-1 RAs are promising as multifactorial treatment for patients with T2DM and/or obesity and CVD, and to improve clinical implementation of guidelines recommending treatment with anti-diabetic drugs with CV benefit.


Prof. Subodh Verma is cardiac surgeon at St. Michael's Hospital and professor at the University of Toronto in Toronto, Ont, Canada


This recording was developed under auspices of PACE-cme. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk A/S.

Or listen to the podcast


This is available as accredited online CME for members. Click the button below to enroll:

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: